1. Home
  2. VERU vs MKTW Comparison

VERU vs MKTW Comparison

Compare VERU & MKTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.65

Market Cap

38.7M

Sector

Health Care

ML Signal

HOLD

Logo MarketWise Inc.

MKTW

MarketWise Inc.

HOLD

Current Price

$16.02

Market Cap

39.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERU
MKTW
Founded
1971
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
38.7M
39.1M
IPO Year
1990
N/A

Fundamental Metrics

Financial Performance
Metric
VERU
MKTW
Price
$2.65
$16.02
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$22.50
$20.00
AVG Volume (30 Days)
203.5K
13.2K
Earning Date
02-12-2026
02-27-2026
Dividend Yield
N/A
4.94%
EPS Growth
N/A
N/A
EPS
N/A
2.55
Revenue
N/A
$342,206,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$6.34
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$9.08
52 Week High
$14.20
$21.74

Technical Indicators

Market Signals
Indicator
VERU
MKTW
Relative Strength Index (RSI) 60.36 59.44
Support Level $2.27 $14.60
Resistance Level $2.49 $15.95
Average True Range (ATR) 0.17 0.61
MACD 0.04 0.18
Stochastic Oscillator 90.60 93.64

Price Performance

Historical Comparison
VERU
MKTW

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.

Share on Social Networks: